TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn’s disease
Journal of Clinical Investigation · 17.09.2024 · 134 (18)
DOI: 10.1172/jci179472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 18.07.2024. Verfasst von Yao Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Center for Immune-Related Diseases, Ruijin Hospital. Hauptthemen laut MEDLINE: Crohn Disease, Twist-Related Protein 1, Fibroblasts, Fibrosis. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Commission.
Abstract (Originalsprache)
Intestinal fibrosis, a severe complication of Crohn’s disease (CD), is characterized by excessive extracellular matrix (ECM) deposition and induces intestinal strictures, but there are no effective antifibrosis drugs available for clinical application. We performed single-cell RNA sequencing (scRNA-Seq) of fibrotic and nonfibrotic ileal tissues from patients with CD with intestinal obstruction. Analysis revealed mesenchymal stromal cells (MSCs) as the major producers of ECM and the increased infiltration of its subset FAP + fibroblasts in fibrotic sites, which was confirmed by immunofluorescence and flow cytometry. Single-cell transcriptomic profiling of chronic dextran sulfate sodium salt murine colitis model revealed that CD81 + Pi16 – fibroblasts exhibited transcriptomic and functional similarities to human FAP + fibroblasts. Consistently, FAP + fibroblasts were identified as the key subtype with the highest level of ECM production in fibrotic intestines. Furthermore, specific knockout or pharmacological inhibition of TWIST1, which was highly expressed by FAP + fibroblasts, could significantly ameliorate fibrosis in mice. In addition, TWIST1 expression was induced by CXCL9 + macrophages enriched in fibrotic tissues via IL-1β and TGF-β signal. These findings suggest the inhibition of TWIST1 as a promising strategy for CD fibrosis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Center for Immune-Related Diseases, Ruijin Hospital.
- Shanghai Institute of Immunology, Department of Immunology and Microbiology, and Ministry of Education Key Laboratory of Cell Death and Differentiation, and.
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Commission
Zitieren
APA
Zhang, Y., Wang, J., Sun, H., Xun, Z., He, Z., Zhao, Y., Qi, J., Sun, S., Yang, Q., Gu, Y., Zhang, L., Zhou, C., Ye, Y., Wu, N., Zou, D., & Su, B. (2024). TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn’s disease. Journal of Clinical Investigation, 134(18). https://doi.org/10.1172/jci179472
Vancouver
Zhang Y, Wang J, Sun H, Xun Z, He Z, Zhao Y, et al. TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn’s disease. Journal of Clinical Investigation. 2024;134(18). doi:10.1172/jci179472
BibTeX
@article{Zhang2024,
author = {Zhang, Yao and Wang, Jiaxin and Sun, Hongxiang and Xun, Zhenzhen and He, Zirui and Zhao, Yizhou and Qi, Jingjing and Sun, Sishen and Yang, Qidi and Gu, Yubei and Zhang, Ling and Zhou, Chunhua and Ye, Youqiong and Wu, Ningbo and Zou, Duowu and Su, Bing},
title = {TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn’s disease},
journal = {Journal of Clinical Investigation},
year = {2024},
volume = {134},
number = {18},
doi = {10.1172/jci179472}
}
EUVIMED